Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial RD McBane II, WE Wysokinski, JG Le‐Rademacher, T Zemla, A Ashrani, ... Journal of thrombosis and haemostasis 18 (2), 411-421, 2020 | 494 | 2020 |
Reversal of the estrogen receptor–negative phenotype in breast cancer and restoration of antiestrogen response J Bayliss, A Hilger, P Vishnu, K Diehl, D El-Ashry Clinical Cancer Research 13 (23), 7029-7036, 2007 | 150 | 2007 |
Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer P Vishnu, V Roy Breast Cancer: Basic and Clinical Research 5, BCBCR. S5857, 2011 | 118 | 2011 |
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma G Chen, X Wang, J Yu, S Varambally, J Yu, DG Thomas, MY Lin, P Vishnu, ... Cancer research 67 (7), 3461-3467, 2007 | 113 | 2007 |
TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort J Hong, E Leung, AG Fraser, TR Merriman, P Vishnu, GW Krissansen Journal of gastroenterology and hepatology 22 (11), 1760-1766, 2007 | 99 | 2007 |
Haematological manifestations of human immune deficiency virus infection P Vishnu, DM Aboulafia British journal of haematology 171 (5), 695-709, 2015 | 94 | 2015 |
Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn's disease in a New Zealand Caucasian cohort E Leung, J Hong, AG Fraser, TR Merriman, P Vishnu, GW Krissansen Immunology and Cell Biology 84 (2), 233-236, 2006 | 70 | 2006 |
Efficacy and cost‐benefit analysis of risk‐adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization P Vishnu, V Roy, A Paulsen, AC Zubair Transfusion 52 (1), 55-62, 2012 | 65 | 2012 |
Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia V Kumar, S Ailawadhi, L Bojanini, A Mehta, S Biswas, T Sher, V Roy, ... Blood cancer journal 9 (10), 75, 2019 | 62 | 2019 |
Update on options for treatment of metastatic castration-resistant prostate cancer P Vishnu, WW Tan OncoTargets and Therapy, 39-51, 2010 | 58 | 2010 |
COVID-19 vaccination associated severe immune thrombocytopenia SRA Shah, S Dolkar, J Mathew, P Vishnu Experimental Hematology & Oncology 10, 1-5, 2021 | 55 | 2021 |
Current therapeutic strategies for invasive and metastatic bladder cancer P Vishnu, J Mathew, WW Tan OncoTargets and therapy, 97-113, 2011 | 55 | 2011 |
Diagnosis and management of genetic iron overload disorders WC Palmer, P Vishnu, W Sanchez, B Aqel, D Riegert-Johnson, ... Journal of general internal medicine 33, 2230-2236, 2018 | 53 | 2018 |
AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy P Vishnu, DM Aboulafia Advances in Hematology 2012, 2012 | 46 | 2012 |
Elevated neutrophil-lymphocyte ratio is predictive of poor outcomes following aneurysmal subarachnoid hemorrhage SA Jamali, MT Turnbull, T Kanekiyo, P Vishnu, AC Zubair, CC Raper, ... Journal of Stroke and Cerebrovascular Diseases 29 (4), 104631, 2020 | 31 | 2020 |
Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia P Vishnu, DM Aboulafia Journal of Blood Medicine, 99-106, 2016 | 31 | 2016 |
Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial DM Arnold, NM Heddle, RJ Cook, C Hsia, M Blostein, E Jamula, ... The Lancet Haematology 7 (9), e640-e648, 2020 | 28 | 2020 |
Utility of bone marrow biopsy and aspirate for staging of diffuse large B cell lymphoma in the era of positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro … P Vishnu, A Wingerson, M Lee, MT Mandelson, DM Aboulafia Clinical Lymphoma Myeloma and Leukemia 17 (10), 631-636, 2017 | 28 | 2017 |
Polymorphisms of CARD15/NOD2 and CD14 genes in New Zealand Crohn's disease patients E Leung, J Hong, AG Fraser, TR Merriman, P Vishnu, WGH Abbott, ... Immunology and cell biology 83 (5), 498-503, 2005 | 28 | 2005 |
Incidence of skin and respiratory immune-related adverse events correlates with specific tumor types in patients treated with checkpoint inhibitors LM Rose, HA DeBerg, P Vishnu, JK Frankel, AB Manjunath, JPE Flores, ... Frontiers in Oncology 10, 570752, 2021 | 27 | 2021 |